QOL Analysis Confers Nivolumab Tolerability Versus Placebo for Esophageal, Gastroesophageal Cancer

Article

Similar results with nivolumab and a matched placebo are reported with preliminary health-related quality-of-life data from the CheckMate 577 trial.

Preliminary findings from the phase 3 CheckMate 577 trial (NCT02743494) presented at the 2021 ASCO Gastrointestinal Cancers Symposium show trends toward improved esophageal-specific and health-related quality of life with nivolumab (Opdivo) in patients with esophageal/gastroesophageal cancer, closely correlating with results observed in a placebo group.

“It was previously reported that nivolumab is the first adjuvant therapy to provide a statistically significant and clinically meaningful improvement in disease-free survival versus a placebo in resected esophageal cancer/gastroesophageal junction cancer following neoadjuvant therapy,” said Eric Van Cutsem, MD, PhD, professor of internal medicine at the University of Leuven in Belgium and head of digestive oncology at the University Hospital Gasthuisberg in Leuven, during the virtual presentation.

The primary end point of this study was disease-free survival (DFS), with secondary end points of overall survival (OS) and OS rates at 1, 2, and 3 years. Investigators enrolled 794 patients, of whom 532 were randomly assigned nivolumab and 262 randomly assigned placebo.

To assess health-related quality of life, general- and disease-related symptoms, and functioning disease burden, investigators used the FACT-E and EQ-5D-3L patient-reported outcome questionnaires. The questionaries were administered at baseline, every 4 weeks during the 12-month treatment, and at post-treatment follow-up visits. Completion rates for patient reports at baseline were 95%, and approximately 90% at 12 months.

At baseline, mean health-related quality of life scores were similar in both groups, and both groups saw an increase in these scores after 1 year.

Scores were similar in the nivolumab and placebo groups for the following: FACT-E total score (133.4 vs. 134.03, respectively), EQ-5D Visual Analogue Scale (70.4 vs. 69.1, respectively) and EQ-5D Utility Index (0.82 vs. 0.831, respectively). The investigators also observed similarities in scores for the esophageal cancer subscale (50.2 vs. 50.1).

Increases in these scores occurred from baseline through most time points through 49 weeks in both groups.

“Patients treated with [nivolumab] did not experience a reduction in [health-related] QoL, further supporting clinical data to demonstrate benefit and tolerability for adjuvant [nivolumab] in patients with resected [esophageal cancer/ gastroesophageal junction cancer],” the investigators concluded in their abstract.

Reference:

Van Cutsem E, Singh P, Cleary JM, et al. Checkmate 577: Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC). Presented at: 2021 ASCO Gastrointestinal Cancers Symposium; January 15-17, 2021; virtual. Abstract 167.

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Related Content